Drug Profile
Influenza A virus H7N9 vaccine - National Resilience
Alternative Names: H7N9 vaccine - National ResilienceLatest Information Update: 18 Jun 2021
Price :
$50
*
At a glance
- Originator Nanotherapeutics
- Developer National Resilience
- Class Influenza A vaccines; Influenza A virus H7N9 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H7N9 subtype
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for preclinical development in Influenza-A virus H7N9 subtype in USA (Parenteral)
- 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
- 25 Oct 2016 Preclinical trials in Influenza-A virus H7N9 subtype in USA (Parenteral)